NEW YORK, NY — As the world enters the second week of October, a month traditionally synonymous with pink ribbons and messages of early detection, a global movement is preparing to shift the spotlight toward a more sobering reality. On October 13, 2026, designated as National Metastatic Breast Cancer (MBC) Awareness Day, the #LightUpMBC campaign will see more than 325 landmarks across 50 U.S. states and 20 countries illuminate in a tri-color display of teal, green, and pink.
The initiative, organized by METAvivor Research and Support, seeks to bridge the gap between general breast cancer awareness and the urgent, unmet needs of those living with Stage 4 disease. Unlike early-stage breast cancer, metastatic breast cancer is currently incurable, claiming an estimated 42,670 lives annually in the United States alone—a figure that translates to approximately 117 deaths every single day.
Main Facts: A Global Beacon for the "Forgotten" Stage
The #LightUpMBC campaign is designed to be a visual and digital catalyst for change. While the "pink" movement has successfully raised awareness for mammograms and early intervention, those within the MBC community often feel sidelined by the celebratory tone of "survivorship." For a Stage 4 patient, there is no "finishing treatment"; there is only the hope that the current line of therapy continues to work until the next scientific breakthrough arrives.
The 2026 campaign is the largest to date, featuring a coordinated illumination of iconic structures including One World Trade Center in New York City, the Willis Tower in Chicago, and the Mactan-Cebu Airport in the Philippines. The colors chosen for the illumination carry deep symbolic weight: teal represents healing and spirituality, green symbolizes the triumph of spring over winter (renewal and hope), and pink signifies the breast cancer origin.
Complementing the physical light displays is #LightUpMBC Live, a high-production virtual event streaming at 8 p.m. ET. This broadcast serves as both a fundraiser and an educational platform, featuring patient testimonials, insights from leading oncologists, and performances by Broadway stars. One hundred percent of the net proceeds from the campaign are funneled directly into Stage 4 research grants, a rarity in a philanthropic landscape where the vast majority of breast cancer funding is directed toward prevention and early-stage awareness.
Chronology: From a Single Bridge to a Worldwide Phenomenon
The evolution of #LightUpMBC is a testament to the power of grassroots advocacy. The movement can be traced back to 2017, when the Memorial Bridge in Portsmouth, New Hampshire, became the first landmark to light up specifically for metastatic breast cancer. This initial spark was inspired by Jessica Moore, a young woman diagnosed with MBC at the age of 32, who passed away in 2014.
Jessica’s wish was simple: she wanted the world to see the "other side" of breast cancer—the side that isn’t cured by a ribbon or a 5K run. Her best friend, Laura Inahara, took up the mantle, founding #LightUpMBC to honor Jessica’s legacy.
- 2017–2019: The campaign began as a localized effort in the Northeast United States, successfully lighting a handful of bridges and city halls.
- 2020–2022: Despite the challenges of the global pandemic, the campaign pivoted to a digital-first strategy. The introduction of #LightUpMBC Live allowed the movement to reach a global audience, and the number of participating landmarks surged past 100.
- 2023–2025: The campaign gained international momentum, with landmarks in Europe, Asia, and South America joining the cause. By 2025, the campaign had raised over $2.7 million for research.
- 2026: The current year marks a historic milestone with over 325 landmarks confirmed. The 2026 broadcast features a sophisticated blend of live on-site reporting from illuminated landmarks and studio performances, reflecting the professionalization and massive scale of the movement.
Supporting Data: The Statistics of a Silent Crisis
The urgency of the #LightUpMBC campaign is underscored by data from the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) program. Metastatic breast cancer occurs when cancer cells break away from the primary tumor in the breast and travel through the lymphatic system or bloodstream to distant organs. The most common sites of metastasis are the bones, liver, lungs, and brain.
The 2026 projections provide a stark look at the disease’s impact:
- Mortality: 42,670 projected deaths in the U.S. for 2026.
- Daily Toll: Approximately 117 people die every day from MBC.
- Diagnosis Trends: While some patients are diagnosed "de novo" (at Stage 4 from the start), nearly 30% of women diagnosed with early-stage breast cancer will eventually see their disease progress to the metastatic stage, sometimes years or even decades after their initial "clear" diagnosis.
- Funding Disparity: Historically, only 2% to 5% of all breast cancer research funding has been dedicated to Stage 4 research. METAvivor was founded specifically to address this imbalance, ensuring that 100% of its research funds go to metastatic projects.
Furthermore, the "No Evidence of Disease" (NED) status, often misunderstood by the public as a "cure," is a precarious state for MBC patients. Data shows that even when scans are clear, microscopic cancer cells can remain dormant, eventually becoming resistant to current therapies. This biological reality necessitates a constant pipeline of new drugs—a pipeline that can only be filled through sustained research funding.
Official Responses: Advocacy in the Face of Adversity
Leadership at METAvivor emphasizes that the campaign is about more than just lights; it is about survival. Dr. Kelly Shanahan, a physician and the METAvivor Board President, has lived with MBC since 2013. Her perspective bridges the gap between clinical understanding and the patient experience.
"When I was diagnosed with metastatic breast cancer in 2013, I certainly didn’t think I’d still be here 13 years later," Dr. Shanahan stated. "My hope and the hope of so many others lies in research. METAvivor-funded research is increasingly important these days because we are the only ones focusing exclusively on the stage that kills. #LightUpMBC is the biggest contributor to this research and is also a way to bring us together as a community."
Laura Inahara, the founder of #LightUpMBC, reflected on the emotional weight of the campaign’s growth. "Jessica Moore died at just 36. She hoped to illuminate one local landmark. Today, her legacy helps families around the world shine a light for the people they love. It has raised over $2.7 million for critical research, but more importantly, it has taught patients how to advocate for themselves in a world that often wants to look away from the terminal nature of this disease."
The 2026 live stream will be hosted by Tami Eagle Bowling, an 11-year MBC "thriver" and the campaign director, alongside Broadway’s Kara Lindsay. Bowling noted that the inclusion of high-profile artists like Victoria Clark and Dorian Harewood helps "humanize the statistics," turning cold data into stories of resilience and art.
Implications: Shifting the Paradigm from Terminal to Chronic
The success of the #LightUpMBC campaign in 2026 signals a significant shift in how society views and treats metastatic disease. The long-term goal of METAvivor is to transition MBC from a terminal diagnosis to a "survivable condition"—a chronic illness that can be managed for decades with a high quality of life, similar to how HIV/AIDS was transformed in the late 1990s.
1. Influence on Research Policy:
By raising millions specifically for Stage 4, METAvivor is influencing the broader scientific community. Their rigorous peer-review process, which involves both scientists and patient advocates, ensures that the most promising "translational" research—studies that can quickly move from the lab to the clinic—gets funded. This pressure often encourages larger institutions like the NIH to re-evaluate their own funding allocations.
2. Psychological Impact on Patients:
For the hundreds of thousands of people living with MBC, the #LightUpMBC campaign provides a sense of visibility. The "Pinktober" focus on early detection can inadvertently create a culture of "blame," where Stage 4 patients feel they somehow failed by not catching the disease early enough. The teal, green, and pink lights serve as a public validation of their struggle and a promise that they have not been forgotten.
3. Global Health Equity:
With landmarks lighting up in 20 countries, the movement is highlighting the global disparity in access to MBC treatments. While new targeted therapies are becoming available in the U.S. and Europe, patients in developing nations often lack access to basic palliative care or the genomic testing required for modern MBC treatment. The international scope of #LightUpMBC is beginning to foster cross-border advocacy aimed at lowering the cost of life-extending drugs.
4. The Future of Oncology:
The 2026 campaign highlights the "scientific perspectives" of MBC, focusing on the burgeoning field of liquid biopsies and immunotherapy. As the campaign raises more funds, the focus is shifting toward "resistance mechanisms"—understanding why a drug stops working and how to prevent that shift.
As the sun sets on October 13, 2026, and the world’s most famous skylines turn teal, green, and pink, the message is clear: awareness is the first step, but research is the only path to a cure. The #LightUpMBC movement has successfully turned a day of mourning into a global call to action, ensuring that for those living with Stage 4 breast cancer, the light of hope remains undimmed.
About the Author
